Low Dose Aspirin for Preterm Preeclampsia Preventionmg/Day Dose in High-risk Patients
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This will be a randomized, open-label, controlled trial of patients at high risk of
developing preeclampsia examining 81 mg/day vs 162mg/day daily acetylsalicylic acid (ASA)
use. Based on screening results, patients will be randomized as outlined below into one of
four groups. The proposed study is a pilot to determine if the higher dose of ASA has
positive impacts on measures that predict preeclampsia, compared to the lower dose. If
positive findings, data from this study could be used to develop a larger trial powered to
determine if the higher ASA dose can improve clinical outcomes.